# ODM-207 in Patients With Advance Solid Tumours

> **NCT03035591** · PHASE1,PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 36 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ODM-207

## Key facts

- **NCT ID:** NCT03035591
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-22
- **Primary completion:** 2019-05-10
- **Final completion:** 2019-05-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03035591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03035591, "ODM-207 in Patients With Advance Solid Tumours". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03035591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*